Paper · 42517907
[Immunotherapy and cell therapy in type 1 diabetes : Current state of research].
Schill S and 4 others. Inn Med (Heidelb), 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. [Immunotherapy and cell therapy in type 1 diabetes : Current state of research]. Papers, record 42517907. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42517907
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 1 | Major topic |
| Immunotherapy | Major topic |
| Cell- and Tissue-Based Therapy | Major topic |
| Humans | |
| Antibodies, Monoclonal, Humanized | |
| Insulin-Secreting Cells | |
| Disease Progression | |
| Autoantibodies | |
| Islets of Langerhans Transplantation |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,180,194 | An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31180194 | PubMed |
| 2 | 37,861,217 | Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37861217 | PubMed |
| 3 | 36,545,154 | Genetic Engineering of Immune Evasive Stem Cell-Derived Islets. | Transpl Int | 2022 | https://conductscience.org/library/papers/36545154 | PubMed |
| 4 | 39,951,130 | Islet Transplantation Versus Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia From the Collaborative Islet Transplant Registry and the T1D Exchange Registry. | Diabetes Care | 2025 | https://conductscience.org/library/papers/39951130 | PubMed |
| 5 | 41,563,349 | Effect of High-Dose Oral Insulin in Children With Stage 1 Type 1 Diabetes: The Fr1da Insulin Intervention Randomized Controlled Trial. | Diabetes Care | 2026 | https://conductscience.org/library/papers/41563349 | PubMed |
| 6 | 40,544,428 | Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40544428 | PubMed |
| 7 | 38,710,228 | [Early Detection Of Type 1 Diabetes By Islet Autoantibody Screening: A Position Paper Of The Fr1daplex Project Leaders And Training Centres, Bvkj Bavaria And Paednetz (Registered) Bavaria]. | Gesundheitswesen | 2025 | https://conductscience.org/library/papers/38710228 | PubMed |
| 8 | 41,237,794 | Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial. | Lancet | 2025 | https://conductscience.org/library/papers/41237794 | PubMed |
| 9 | 37,329,450 | Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. | Diabetologia | 2023 | https://conductscience.org/library/papers/37329450 | PubMed |
| 10 | 38,055,252 | Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes. | N Engl J Med | 2023 | https://conductscience.org/library/papers/38055252 | PubMed |
1 to 10 of 27
See all 27 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| INS | 3,630 | PubTator's text mining | https://conductscience.org/library/genes/3630 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42517907
GET https://conductscience.org/api/papers/v1/42517907/references?page=2